Compare Southern Copper Corp (SCCO) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Southern Copper Corp trades at $204 (market cap $167.74B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Southern Copper Corp is far larger — about 2.9× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Southern Copper Corp for 61 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SCCO | TAK | |
|---|---|---|
Market Cap | $167.74B | $58.74B |
Volume | 853,110 | 3,110,994 |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $19.05 |
52-Week Low | $120.02 | $13.23 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | $169.03B | $86.65B |
Dividend Yield | 2.21% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCCO trades at $200.57, down 1.81% on the day, with technical indicators showing neutral momentum. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026 and impressive profitability margins including 35.87% net income margin. Recent earnings beats and a $10.2B Mexican project pipeline support growth prospects, though the stock trades at premium valuations with P/E of 30.1 and P/S of 10.82.
While SCCO's operational strength and copper demand from AI infrastructure provide upside potential, the stock faces headwinds from its premium valuation relative to peers and mixed analyst sentiment with only 10.34% buy ratings. The current price sits above the consensus target of $167.67, suggesting limited near-term upside despite strong cash flow generation and dividend payments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
